1. Home
  2. NTLA vs PLAB Comparison

NTLA vs PLAB Comparison

Compare NTLA & PLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • PLAB
  • Stock Information
  • Founded
  • NTLA 2014
  • PLAB 1969
  • Country
  • NTLA United States
  • PLAB United States
  • Employees
  • NTLA N/A
  • PLAB N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • PLAB Semiconductors
  • Sector
  • NTLA Health Care
  • PLAB Technology
  • Exchange
  • NTLA Nasdaq
  • PLAB Nasdaq
  • Market Cap
  • NTLA 1.4B
  • PLAB 1.6B
  • IPO Year
  • NTLA 2016
  • PLAB 1987
  • Fundamental
  • Price
  • NTLA $13.80
  • PLAB $24.44
  • Analyst Decision
  • NTLA Buy
  • PLAB
  • Analyst Count
  • NTLA 17
  • PLAB 0
  • Target Price
  • NTLA $56.63
  • PLAB N/A
  • AVG Volume (30 Days)
  • NTLA 3.1M
  • PLAB 331.3K
  • Earning Date
  • NTLA 11-07-2024
  • PLAB 12-11-2024
  • Dividend Yield
  • NTLA N/A
  • PLAB N/A
  • EPS Growth
  • NTLA N/A
  • PLAB 18.80
  • EPS
  • NTLA N/A
  • PLAB 2.27
  • Revenue
  • NTLA $43,086,000.00
  • PLAB $871,791,000.00
  • Revenue This Year
  • NTLA $50.73
  • PLAB N/A
  • Revenue Next Year
  • NTLA $8.69
  • PLAB $9.01
  • P/E Ratio
  • NTLA N/A
  • PLAB $10.77
  • Revenue Growth
  • NTLA N/A
  • PLAB N/A
  • 52 Week Low
  • NTLA $12.82
  • PLAB $20.25
  • 52 Week High
  • NTLA $34.87
  • PLAB $34.16
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 36.15
  • PLAB 52.13
  • Support Level
  • NTLA $12.82
  • PLAB $23.42
  • Resistance Level
  • NTLA $17.30
  • PLAB $26.30
  • Average True Range (ATR)
  • NTLA 1.11
  • PLAB 0.72
  • MACD
  • NTLA -0.11
  • PLAB -0.07
  • Stochastic Oscillator
  • NTLA 19.56
  • PLAB 45.61

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About PLAB Photronics Inc.

Photronics Inc is a U.S.-based company that is principally engaged in manufacturing photomasks. The photomasks are photographic quartz plates that contain microscopic images of electronic circuits that are used as a component in the manufacture of integrated circuits and flat-panel displays. The revenue from products designed for integrated circuits production accounts for the majority of total revenue, with the rest derived from products for flat-panel display production. The company's assets are located in Taiwan, Korea, and the United States. It generates revenue worldwide, including in the United States, Europe, Taiwan, Korea, China, and elsewhere in Asia, with Taiwan contributing the majority of total revenue.

Share on Social Networks: